Krystal Biotech (4KB) Price & Analysis

1 Followers

4KB Stock Chart & Stats

€307.60

€0.20(0.07%)

At close: Jul 27 4:00 PM EDT

€307.60

€0.20(0.07%)

Day’s Range― - ―

52-Week Range€116.55 - €330.20

Previous CloseN/A

Volume40.00

Average Volume (3M)5.00

Market Cap

€9.13B

Enterprise Value€10.56K

Total Cash (Recent Filing)€845.63M

Total Debt (Recent Filing)€8.85M

Price to Earnings (P/E)43.3

Beta0.08

Next Earnings

Nov 09, 2026

EPS Estimate

1.62

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)8.27

Shares Outstanding29,598,837

10 Day Avg. Volume6

30 Day Avg. Volume5

Financial Highlights & Ratios

PEG Ratio0.27

Price to Book (P/B)5.85

Price to Sales (P/S)18.34

P/FCF Ratio37.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€346.74

Price Target Upside12.72% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)6.58

Revenue Forecast (FY)€432.82M

Bulls Say, Bears Say

Bulls Say

VYJUVEK Commercial GrowthVYJUVEK is demonstrating sustained commercial traction, with strong year-over-year revenue growth and broadening reimbursement access. More than 60% penetration of the diagnosed DEB pool supports durable patient adoption, while expanding approvals can provide a foundation for continued sales growth.

Profitability And Cash GenerationStrong cash conversion indicates that reported profitability is translating into internally generated funds rather than relying primarily on financing. This gives Krystal resources to support commercialization and pipeline investment while preserving flexibility through changing biotech spending cycles.

Pipeline And International Regulatory ExpansionU.K. authorization expands the commercial footprint of the lead therapy and establishes an additional regulated market for future growth. Meanwhile, multiple registrational programs and planned submissions create opportunities to broaden the product base beyond the current DEB indication.

Bears Say

International Reimbursement UncertaintyUnresolved pricing and reimbursement decisions can delay patient access and make international revenue less predictable. Germany has already required a pricing accrual, and staggered decisions across major markets could limit the pace and visibility of overseas expansion.

Small-cohort Pipeline EvidenceSeveral pipeline programs remain supported by very small early-stage studies, making safety, efficacy, and commercial potential difficult to assess with confidence. Registrational progression depends on supportive results, so future portfolio expansion remains exposed to clinical interpretability risk.

Reliance On VYJUVEKThe current revenue model is concentrated around one commercial product, so patient identification, prescriber adoption, distribution, and payer coverage all have an outsized effect on results. Until additional programs reach commercialization, this concentration remains a structural execution risk.

Krystal Biotech News

Krystal Biotech initiated with an Outperform at RBC Capital

RBC Capital analyst Lisa Walter initiated coverage of Krystal Biotech (KRYS) with an Outperform rating and $400 price...

22d ago

KRYS

Micron upgraded, Cisco downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

22d ago

Krystal Biotech Earnings Call Signals Profitable Growth

Krystal Biotech, Inc. (($KRYS)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

KRYS

Alec Stranahan Maintains Buy on Krystal Biotech, Slightly Lowers Price Target to $392 Amid Strong Vyjuvek Momentum and Pipeline Catalysts

Analyst Alec Stranahan from Bank of America Securities reiterated a Buy rating on Krystal Biotech and decreased the...

1M ago

KRYS

Krystal Biotech price target lowered to $392 from $396 at BofA

BofA analyst Alec Stranahan lowered the firm’s price target on Krystal Biotech (KRYS) to $392 from $396 and...

1M ago

KRYS

Krystal Biotech price target raised to $386 from $378 at Citi

Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $386 from $378 and...

1M ago

KRYS

Analyst Backs Krystal with Buy Rating on Vyjuvek Launch Momentum and Rare-Disease Pipeline Upside

William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating today....

1M ago

KRYS

Morning Movers: Supernus and Indivior jump following merger pact

Stock futures are higher as investors begin a new month with improving risk appetite after easing tensions in...

1M ago

AZN

BMY

Krystal Biotech reports Q2 EPS $1.79, consensus $1.91

Reports Q2 revenue $119.22M, consensus $121.04M. “Our second quarter reflects the strength of the Krystal model: a global...

1M ago

KRYS

KRYS Upcoming Earnings Report: What to Expect?

Krystal Biotech, Inc. (KRYS) is scheduled to report 2nd quarter earnings on 08/03/2026, before the market opens. Regarding...

1M ago

KRYS

Krystal Biotech Updates KB801 Patent Office Filing

The latest update is out from Krystal Biotech ( ($KRYS) ). On July 21, 2026, Krystal Biotech filed...

2M ago

KRYS

Krystal Biotech to replace Taylor Morrison in S&P 400 at open on 7/24

Berkshire Hathaway (BRK.B) (BRK.A) (BRK.A/BRK.B) is acquiring Taylor Morrison Home (TMHC) in a deal expected to close on...

2M ago

KRYS

TMHC

Tutor Perini to replace Krystal Biotech in S&P 600 at open on 7/24

17:18 EDT Tutor Perini (TPC) to replace Krystal Biotech (KRYS) in S&P 600 at open on 7/24 Published...

2M ago

TPC

KRYS

Krystal Biotech price target raised to $396 from $364 at BofA

BofA raised the firm’s price target on Krystal Biotech (KRYS) to $396 from $364 and keeps a Buy...

2M ago

KRYS

4KB FAQ

What was Krystal Biotech’s price range in the past 12 months?

Krystal Biotech lowest stock price was €116.55 and its highest was €330.20 in the past 12 months.

What is Krystal Biotech’s market cap?

Krystal Biotech’s market cap is €9.13B.

When is Krystal Biotech’s upcoming earnings report date?

Krystal Biotech’s upcoming earnings report date is Nov 09, 2026 which is in 63 days.

How were Krystal Biotech’s earnings last quarter?

Krystal Biotech released its earnings results on Aug 03, 2026. The company reported €1.552 earnings per share for the quarter, beating the consensus estimate of €1.475 by €0.077.

Is Krystal Biotech overvalued?

According to Wall Street analysts Krystal Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Krystal Biotech pay dividends?

Krystal Biotech does not currently pay dividends.

What is Krystal Biotech’s EPS estimate?

Krystal Biotech’s EPS estimate is 1.62.

How many shares outstanding does Krystal Biotech have?

Krystal Biotech has 29,598,837 shares outstanding.

What happened to Krystal Biotech’s price movement after its last earnings report?

Krystal Biotech reported an EPS of €1.552 in its last earnings report, beating expectations of €1.475. Following the earnings report the stock price went down -4.927%.

Which hedge fund is a major shareholder of Krystal Biotech?

Currently, no hedge funds are holding shares in DE:4KB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Krystal Biotech Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

31.82%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Krystal Biotech

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Krystal Biotech (4KB) Earnings & Revenues

Historic Earnings Reports

4KB Company Deck

4KB Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented multiple strong commercial and financial highlights — double‑digit revenue growth (+24% YoY), improved gross margin (95%), expanded U.S. reimbursement (>730 approvals), robust cash (> $1.1B), and advancing clinical programs with several near‑term readouts and encouraging oncology signals. Lowlights were primarily operational and timing risks tied to international pricing/reimbursement (notably a German accrual that depressed reported EMEA revenue), country‑specific access constraints, modest increases in G&A, and the small size/early stage of several repeat‑dose studies. Overall, the positives around revenue, profitability, cash position, and pipeline momentum outweigh the near‑term access and timing headwinds, supporting a constructive outlook.View all DE:4KB earnings summaries

4KB Stock 12 Month Forecast

Average Price Target

€346.74

▲(12.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"€124","409":"€409","195.25":"€195.3","266.5":"€266.5","337.75":"€337.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":408.16642914,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€408.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":346.74053896000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€346.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":310.86093021,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€310.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,195.25,266.5,337.75,409],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.8,319.2128022415385,326.6256044830769,334.0384067246154,341.45120896615384,348.86401120769233,356.27681344923076,363.68961569076924,371.1024179323077,378.51522017384616,385.9280224153846,393.3408246569231,400.75362689846156,{"y":408.16642914,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.8,314.48773376615384,317.1754675323077,319.86320129846155,322.55093506461543,325.23866883076926,327.9264025969231,330.61413636307697,333.3018701292308,335.9896038953846,338.6773376615385,341.3650714276923,344.0528051938462,{"y":346.74053896000004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,311.8,311.7277638623077,311.6555277246154,311.5832915869231,311.51105544923075,311.43881931153845,311.36658317384615,311.29434703615385,311.22211089846155,311.14987476076925,311.0776386230769,311.0054024853846,310.9331663476923,{"y":310.86093021,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":125.05,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.1,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.65,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":214.2,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.8,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.3,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.1,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.2,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314.6,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":311.8,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >